Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2008

01-10-2008 | Erratum

Erratum to: BCoR-L1variation and breast cancer

Authors: Felicity Lose, Jeremy Arnold, David B Young, Carolyn J Brown, Graham J Mann, Gulietta M Pupo, Kum Kum Khanna, Georgia Chenevix-Trench, Amanda B Spurdle, The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer

Published in: Breast Cancer Research | Issue 5/2008

Login to get access

Excerpt

Following the publication of our article [1] we noticed that, due to a production error, the figure legends and images were incorrectly matched. All legends were correctly placed, and cited in the text, but were associated with the wrong image. …
Appendix
Available only for authorised users
Literature
1.
Lose F, Arnold J, Young DB, Brown CJ, Mann GJ, Pupo GM, The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Khanna KK, Chenevix-Trench G, Spurdle AB: BcoR-L1 variation and breast cancer. Breast Cancer Res. 2007, 9: R54-10.1186/bcr1759.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: BCoR-L1variation and breast cancer
Authors
Felicity Lose
Jeremy Arnold
David B Young
Carolyn J Brown
Graham J Mann
Gulietta M Pupo
Kum Kum Khanna
Georgia Chenevix-Trench
Amanda B Spurdle
The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer
Publication date
01-10-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2153

Other articles of this Issue 5/2008

Breast Cancer Research 5/2008 Go to the issue

Research article

Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma

Research article

Targeting aspartate aminotransferase in breast cancer

Research article

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

Research article

A candidate molecular signature associated with tamoxifen failure in primary breast cancer

Editorial

The evolving role of oestrogen receptor β in clinical breast cancer

Research article

Selective segregation of DNA strands persists in long label retaining mammary cells during pregnancy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits